NCT05439863

TAVR for Aortic Valve Disease

Transcatheter Aortic Valve Replacement for Severe Aortic Valve Disease: Multi-center, Real-word Registry

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 5,000 (estimated)
• Sponsor: Nanjing First Hospital, Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.

Conditions

• Aortic Valve Disease

Interventions

Type	Name	Description
DEVICE	transcatheter heart valve	patients with severe aortic valve disease underwent transcatheter heart valve

Timeline

• Start date: 2022-07-01
• Primary completion: 2032-12-30
• Completion: 2037-12-30
• First posted: 2022-06-30
• Last updated: 2024-11-15

Locations

1 site across 1 country: China